Abaloparatide
Abaloparatide is a synthetic 34-amino acid analog of parathyroid hormone-related protein (PTHrP 1-34), FDA-approved in 2017 for postmenopausal osteoporosis. It selectively binds the RG conformation of the PTH1R receptor, producing potent anabolic bone formation with lower hypercalcemia incidence than teriparatide.
Abaloparatide is a synthetic 34-amino acid peptide analog of human parathyroid hormone-related protein (PTHrP 1-34). Marketed as Tymlos (Radius Health), it was FDA-approved in 2017 for the treatment of postmenopausal women with osteoporosis at high fracture risk.
Overview
Abaloparatide emerged from the understanding that PTH and PTHrP, despite sharing the PTH1R receptor, produce different signaling kinetics and biological outcomes. PTHrP produces more transient receptor activation than PTH, and this transience favors bone formation over resorption. Abaloparatide was engineered to optimize this selectivity by preferentially binding the RG (guanine nucleotide-sensitive, signaling-competent) conformation of PTH1R, rather than the R0 (guanine nucleotide-insensitive, internalization-favoring) conformation that PTH also engages.
The clinical result is an anabolic bone agent that rivals or exceeds teriparatide in BMD gains at certain sites while producing significantly less hypercalcemia — a meaningful advantage for patient tolerability and safety monitoring. Abaloparatide joins teriparatide and romosozumab as the three available anabolic bone agents, expanding the therapeutic armamentarium for severe osteoporosis.
Mechanism of Action
Selective PTH1R Binding (RG Conformation)
PTH1R exists in two conformational states:
- RG conformation: G protein-coupled, signaling-competent state. Ligand binding to RG triggers cAMP production and downstream osteoblast activation, with rapid dissociation and transient signaling.
- R0 conformation: G protein-uncoupled state. Ligand binding to R0 produces prolonged receptor occupancy, sustained cAMP signaling, and receptor internalization.
Abaloparatide binds RG with high affinity but has lower affinity for R0 compared to PTH 1-34. This RG selectivity produces:
- Transient cAMP response: Brief, potent osteoblast activation followed by rapid signal termination.
- Less sustained signaling: Reduced prolonged cAMP elevation, which is associated with bone resorption and hypercalcemia.
- Favorable formation/resorption ratio: The transient signaling profile preferentially stimulates bone formation over resorption (Hattersley et al., 2016).
Downstream Bone Formation Pathways
Like teriparatide, abaloparatide activates osteoblast formation through:
- cAMP/PKA/CREB signaling: Drives osteoblast differentiation gene transcription.
- Wnt pathway activation: Suppresses sclerostin, activating canonical Wnt signaling.
- Osteoblast survival: Anti-apoptotic effects on osteoblasts and osteocytes.
- Modeling-based formation: Evidence suggests abaloparatide may stimulate more modeling-based (adding bone to surfaces without prior resorption) versus remodeling-based formation compared to teriparatide, though this remains under investigation (Bahar et al., 2016).
Comparison of Receptor Pharmacology
| Property | PTH 1-34 | PTHrP 1-36 | Abaloparatide |
|---|---|---|---|
| RG binding affinity | High | High | High |
| R0 binding affinity | High | Low | Low |
| cAMP response duration | Prolonged | Transient | Transient |
| Hypercalcemia potential | Moderate | Low | Low |
| Bone formation potency | High | High | High |
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Head-to-Head with Teriparatide
The ACTIVE trial provided the first direct comparison of abaloparatide and teriparatide within a single randomized trial:
| Outcome (18 months) | Abaloparatide | Teriparatide | Placebo |
|---|---|---|---|
| Spine BMD change | +11.2% | +8.6% | +0.6% |
| Total hip BMD change | +4.2% | +2.6% | -0.1% |
| Femoral neck BMD change | +3.6% | +2.2% | -0.4% |
| Vertebral fracture RR | -86% | -80% | — |
| Hypercalcemia incidence | 3.4% | 6.4% | 0.4% |
The greater BMD gains at hip sites are particularly notable, as hip fractures carry the highest morbidity and mortality among osteoporotic fractures. However, the trial was not powered for direct statistical comparison of fracture outcomes between the two active treatments.
BMD Response Kinetics
Abaloparatide produces notably rapid BMD gains in the first 6 months of therapy:
- Lumbar spine: ~7% at 6 months, reaching ~11% at 18 months
- Total hip: ~3% at 6 months, reaching ~4% at 18 months
- Clinical significance: The rapid early response may translate to earlier fracture risk reduction, particularly important for patients at imminent fracture risk
Bone turnover markers show a characteristic pattern:
- P1NP (formation): Rapid early increase, peaking at ~1 month, then gradually declining
- CTX (resorption): More gradual increase, smaller magnitude than P1NP
- Net effect: The formation-resorption differential (anabolic window) is more pronounced and earlier with abaloparatide than with teriparatide
ACTIVExtend Follow-up
The ACTIVExtend trial continued ACTIVE participants into a 24-month open-label alendronate extension phase. Patients who had received abaloparatide followed by alendronate showed:
- Sustained fracture protection: 84% relative risk reduction in new vertebral fractures over the combined 43-month period (18 months abaloparatide + 24 months alendronate) compared to 24 months alendronate alone.
- Continued BMD gains: Additional lumbar spine BMD increases of ~3% during the alendronate phase, building on prior abaloparatide gains. Total hip BMD was maintained or slightly increased.
- Non-vertebral fracture reduction: 39% over the combined period.
This trial was instrumental in establishing the anabolic-to-antiresorptive sequential therapy paradigm (Cosman et al., 2019).
Transdermal Patch Development (ABTS)
A significant advancement in development is the abaloparatide-patch (abaloparatide-sBCTP), a wearable solid microstructured transdermal system (sMTS):
- Technology: Microneedle patch applied to the abdomen for ~5 minutes, delivering abaloparatide through the skin.
- Phase 2 results: The transdermal patch (300 mcg dose) produced BMD increases comparable to subcutaneous abaloparatide at the lumbar spine, with a favorable tolerability profile.
- Phase 3 (wearABLe study): Ongoing evaluation of the patch system for ease of use and compliance advantages. If approved, it would be the first transdermal anabolic osteoporosis therapy, potentially improving adherence by eliminating injection burden.
- Pharmacokinetics: The patch produces a slightly different PK profile (broader Tmax) than SC injection, but maintains the transient signaling pattern critical for bone anabolism (Cosman et al., 2020).
Cortical vs. Trabecular Bone Effects
A distinguishing feature of abaloparatide is its effect on cortical bone:
- Both abaloparatide and teriparatide increase trabecular bone volume and connectivity.
- Abaloparatide may produce more favorable cortical bone outcomes, with less cortical porosity increase during treatment compared to teriparatide.
- HR-pQCT studies suggest abaloparatide increases cortical thickness and bone strength at the radius and tibia, sites that are predominantly cortical (Bilezikian et al., 2018).
ACTIVE Trial (Pivotal Phase 3)
The Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) was a 18-month randomized, double-blind, placebo- and active-controlled trial in 2,463 postmenopausal women with osteoporosis. Key results:
- Vertebral fractures: Abaloparatide reduced new vertebral fractures by 86% vs. placebo (0.58% vs. 4.22%, p<0.001). Teriparatide reduced them by 80%.
- Non-vertebral fractures: Abaloparatide reduced non-vertebral fractures by 43% vs. placebo (2.7% vs. 4.7%, p=0.049). Teriparatide did not reach significance vs. placebo in this trial.
- Major osteoporotic fractures: Abaloparatide reduced these by 70% vs. placebo.
- BMD gains (18 months): Lumbar spine +11.2% (abaloparatide) vs. +8.6% (teriparatide) vs. +0.6% (placebo). Total hip +4.2% vs. +2.6% vs. -0.1%. Femoral neck +3.6% vs. +2.2% vs. -0.4%.
- Hypercalcemia: 3.4% with abaloparatide vs. 6.4% with teriparatide (significant difference) (Miller et al., 2016).
Safety Profile
Abaloparatide has a favorable safety profile established in the ACTIVE and ACTIVExtend trials:
- Common adverse effects: Injection site reactions (redness 14%, edema 9%), dizziness (10%), nausea (8%), headache (8%), palpitations (2%).
- Hypercalcemia: 3.4% incidence (vs. 6.4% with teriparatide in ACTIVE) — a significant clinical advantage. Serum calcium monitoring is still recommended.
- Heart rate: Small transient increases (~5 bpm) observed post-injection, resolving within hours. No significant cardiovascular events.
- Orthostatic hypotension: Reported in 4% of patients.
- Antibody development: Low immunogenicity. Anti-abaloparatide antibodies developed in ~49% of patients but were non-neutralizing and had no effect on efficacy or safety.
Black Box Warning
Like teriparatide, abaloparatide carries a black box warning regarding osteosarcoma risk based on rat studies (dose-dependent osteosarcoma in Fischer 344 rats with long-duration, high-dose exposure). Treatment duration is limited to 2 years (cumulative lifetime exposure to anabolic bone agents). The same caveats apply regarding the poor translatability of the rat model to humans.
Contraindications
- Patients at increased risk for osteosarcoma (Paget's disease, unexplained elevated alkaline phosphatase, open epiphyses, prior skeletal radiation)
- Pre-existing hypercalcemia
- Severe renal impairment (limited data)
Pharmacokinetic Profile
Abaloparatide — Pharmacokinetic Curve
Subcutaneous injection (80 mcg/day)Quick Start
- Typical Dose
- 80 mcg
- Frequency
- Once daily
- Route
- Subcutaneous injection (80 mcg/day)
- Cycle Length
- Up to 2 years (lifetime maximum)
- Storage
- Refrigerate pre-filled pen at 2-8°C, do not freeze. Discard after 30 days even if medication remains
Molecular Structure
- Formula
- C174H300N56O49S2
- Weight
- 3 Da
- Length
- 34 amino acids
- CAS
- 247062-33-5
- PubChem CID
- 76943386
- Exact Mass
- 3959.2738 Da
- LogP
- -20.9
- TPSA
- 1740 Ų
- H-Bond Donors
- 61
- H-Bond Acceptors
- 60
- Rotatable Bonds
- 145
- Complexity
- 9310
Identifiers (SMILES, InChI)
InChI=1S/C174H300N56O49/c1-26-93(20)136(228-165(274)126(80-232)224-141(250)101(39-28-32-56-176)200-129(236)78-195-140(249)100(38-27-31-55-175)201-161(270)123(73-133(243)244)223-160(269)121(71-98-76-190-82-197-98)220-158(267)118(68-90(14)15)216-155(264)114(64-86(6)7)213-148(257)107(45-50-127(180)234)207-159(268)120(70-97-75-189-81-196-97)219-151(260)111(49-54-132(241)242)209-164(273)125(79-231)225-167(276)135(92(18)19)227-139(248)94(21)179)168(277)210-108(46-51-128(181)235)149(258)222-124(74-134(245)246)162(271)217-112(62-84(2)3)152(261)205-105(44-37-61-194-173(187)188)143(252)203-103(42-35-59-192-171(183)184)142(251)204-104(43-36-60-193-172(185)186)144(253)206-110(48-53-131(239)240)150(259)214-115(65-87(8)9)154(263)215-113(63-85(4)5)153(262)208-109(47-52-130(237)238)147(256)202-102(40-29-33-57-177)145(254)211-116(66-88(10)11)156(265)218-119(69-91(16)17)166(275)230-174(24,25)170(279)226-106(41-30-34-58-178)146(255)212-117(67-89(12)13)157(266)221-122(72-99-77-191-83-198-99)163(272)229-137(96(23)233)169(278)199-95(22)138(182)247/h75-77,81-96,100-126,135-137,231-233H,26-74,78-80,175-179H2,1-25H3,(H2,180,234)(H2,181,235)(H2,182,247)(H,189,196)(H,190,197)(H,191,198)(H,195,249)(H,199,278)(H,200,236)(H,201,270)(H,202,256)(H,203,252)(H,204,251)(H,205,261)(H,206,253)(H,207,268)(H,208,262)(H,209,273)(H,210,277)(H,211,254)(H,212,255)(H,213,257)(H,214,259)(H,215,263)(H,216,264)(H,217,271)(H,218,265)(H,219,260)(H,220,267)(H,221,266)(H,222,258)(H,223,269)(H,224,250)(H,225,276)(H,226,279)(H,227,248)(H,228,274)(H,229,272)(H,230,275)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H4,183,184,192)(H4,185,186,193)(H4,187,188,194)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,135-,136-,137-/m0/s1
BVISQZFBLRSESR-XSCWXTNMSA-NResearch Indications
Osteoporosis (FDA-Approved)
FDA-approved for postmenopausal women with osteoporosis at high risk for fracture or who have failed other therapies.
FDA-approved for men with osteoporosis at high risk for fracture or intolerant to other treatments.
Bone Health Research
Phase III trials demonstrated substantial reduction in vertebral and nonvertebral fractures.
ACTIVExtend trial showed benefits of abaloparatide followed by alendronate for maintained bone protection.
Research Protocols
subcutaneous Injection
Abaloparatide is administered as a once-daily subcutaneous injection in the periumbilical (around the navel) region of the abdomen. It comes in pre-filled pen devices (Tymlos). Cumulative lifetime use is limited to 2 years due to theoretical osteosarcoma risk observed in rodent studies. A transdermal patch formulation is also in development.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Osteoporosis treatment | 80 mcg | Once daily | —(Route: SubQ (periumbilical abdomen)) |
Reconstitution Guide (mg vial + mL BAC water)
- Store pen refrigerated at 2-8°C (do not freeze)
- Allow to reach room temperature before injection
- Attach new needle for each injection
- Inject subcutaneously in periumbilical region
- Rotate injection sites
- Discard pen after 30 days even if medication remains
Interactions
What to Expect
What to Expect
Bone formation markers increase; initial BMD changes begin
Significant BMD increases at spine, hip, and femur
Continued bone density improvements; fracture risk reduction
Maximum benefits in ACTIVE trial; substantial fracture reduction
Transition to maintenance therapy (e.g., bisphosphonates) recommended
Safety Profile
Common Side Effects
- Hypercalciuria (high calcium in urine)
- Dizziness
- Nausea
- Headache
- Palpitations
- Fatigue
- Upper abdominal pain
- Vertigo
- Injection site reactions
Contraindications
- Paget's disease of bone
- Prior external beam or implant radiation therapy to skeleton
- Bone metastases or history of skeletal malignancies
- Metabolic bone diseases other than osteoporosis
- Pre-existing hypercalcemia
- Pregnancy or nursing
- Cumulative use exceeding 2 years lifetime
Discontinue If
- Signs of hypercalcemia (confusion, fatigue, excessive thirst)
- Persistent bone pain
- Severe dizziness or fainting
- Allergic reactions
Quality Indicators
What to look for
- Clear, colorless solution
- Pharmaceutical grade (Tymlos/Eladynos)
- Proper cold chain maintained
- Intact pen device
- Within expiration date
Caution
- Research-grade products lack FDA oversight
- Temperature excursions may affect potency
Red flags
- Cloudy or discolored solution
- Particulates visible
- Exposed to freezing or high temperatures
- Damaged pen device
Frequently Asked Questions
References (12)
- [1]Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis (ACTIVE Trial) (2016)
- [3]Phase 2 Dose-finding Study of BA058 in Postmenopausal Women (2015)
- [6]Cosman F et al Romosozumab and antiresorptive treatment: the importance of treatment sequence Osteoporos Int (2019)
- [5]
- [10]Bilezikian JP et al Abaloparatide in the treatment of postmenopausal osteoporosis: efficacy and safety results from phase 2 and 3 clinical trials Curr Med Res Opin (2018)
- [11]Leder BZ et al Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in healthy postmenopausal women J Clin Endocrinol Metab (2015)
- [7]Hattersley G et al Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling Endocrinology (2016)
- [12]Bone HG et al ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis J Clin Endocrinol Metab (2018)
- [8]Bahar H et al Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mass and strength in ovariectomized rats Calcif Tissue Int (2016)
- [9]Cosman F et al Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS) Osteoporos Int (2020)
- [2]
- [4]
Peptides A-Z
457 research peptide profiles organized by category. Every entry is backed by peer-reviewed citations.
ACE-031
ACE-031 (ramatercept) is a soluble activin receptor type IIB-Fc fusion protein that binds and neutralizes myostatin and related ligands, with research applications in muscle-wasting disorders, bone density enhancement, and cancer-related cachexia.